Insulet and Dexcom decide not to pursue a joint development agreement to integrate Dexcom's continuous glucose monitoring technology with Insulet's insulin-infusing OmniPod.
Diabetes technology makers Insulet (NSDQ:PODD) and Dexcom Inc. (NSDQ:DXCM) abandoned a 5-year-old joint development deal that would have merged Dexcom's continuous glucose monitoring technology with Insulet's OmniPod insulin delivery system, officials confirmed with MassDevice.com today.
The pair parted ways over differences in their vision for the future of diabetes management technology. Each wants to lower the quantity of devices a diabetic patient must carry in order to manage the disease, but are pursuing diverging avenues for integrating existing monitoring and treatment technologies.
Insulet aims to reduce the number of skin-worn devices while Dexcom is looking to shift its monitoring systems onto the smartphones that patients already have in their pockets.